1
|
Wang K, Xue M, Qiu J, Liu L, Wang Y, Li R, Qu C, Yue W, Tian H. Genomics Analysis and Nomogram Risk Prediction of Occult Lymph Node Metastasis in Non-Predominant Micropapillary Component of Lung Adenocarcinoma Measuring ≤ 3 cm. Front Oncol 2022; 12:945997. [PMID: 35912197 PMCID: PMC9326108 DOI: 10.3389/fonc.2022.945997] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Accepted: 06/21/2022] [Indexed: 11/22/2022] Open
Abstract
Background The efficacy of sublobar resection and selective lymph node dissection is gradually being accepted by thoracic surgeons for patients within early-stage non-small cell lung cancer (NSCLC). Nevertheless, there are still some NSCLC patients develop lymphatic metastasis at clinical T1 stage. Lung adenocarcinoma with a micropapillary (MP) component poses a higher risk of lymph node metastasis and recurrence even when the MP component is not predominant. Our study aimed to explore the genetic features and occult lymph node metastasis (OLNM) risk factors in patients with a non-predominant micropapillary component (NP-MPC) in a large of patient’s cohort with surgically resected lung adenocarcinoma. Methods Between January 2019 and December 2021, 6418 patients who underwent complete resection for primary lung adenocarcinoma at the Qilu Hospital of Shandong University. In our study, 442 patients diagnosed with lung adenocarcinoma with NP-MPC with a tumor size ≤3 cm were included. Genetic alterations were analyzed using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Abnormal protein expression of gene mutations was validated using immunohistochemistry. A nomogram risk model based on clinicopathological parameters was developed to predict OLNM. This model was invalidated using the calibration plot and concordance index. Results In our retrospective cohort, the incidence rate of the micropapillary component was 11.17%, and OLNM was observed in 20.13% of the patients in our study. ARMS-PCR suggested that EGFR exon 19 del was the most frequent alteration in NP-MCP patients compared with other gene mutations (frequency: 21.2%, P<0.001). Patients harboring exon 19 del showed significantly higher risk of OLNM (P< 0.001). A nomogram was developed based on five risk parameters, which showed good calibration and reliable discrimination ability (C-index = 0.84) for evaluating OLNM risk. Conclusions. Intense expression of EGFR exon 19 del characterizes lung adenocarcinoma in patients with NP-MCP and it’s a potential risk factor for OLNM. We firstly established a nomogram based on age, CYFRA21-1 level, tumor size, micropapillary and solid composition, that was effective in predicting OLNM among NP-MCP of lung adenocarcinoma measuring ≤ 3 cm.
Collapse
Affiliation(s)
- Kun Wang
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Mengchao Xue
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Jianhao Qiu
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Ling Liu
- Department of Pathology, Qilu Hospital of Shandong University, Jinan, China
| | - Yueyao Wang
- Department of Pathology, Qilu Hospital of Shandong University, Jinan, China
| | - Rongyang Li
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Chenghao Qu
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Weiming Yue
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
| | - Hui Tian
- Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China
- *Correspondence: Hui Tian,
| |
Collapse
|
2
|
Heldwein MB, Schlachtenberger G, Doerr F, Menghesha H, Bennink G, Schroeder KM, Schaefer SC, Wahlers T, Hekmat K. Different pulmonary adenocarcinoma growth patterns significantly affect survival. Surg Oncol 2021; 40:101674. [PMID: 34896910 DOI: 10.1016/j.suronc.2021.101674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 11/14/2021] [Indexed: 12/25/2022]
Abstract
OBJECTIVE Adenocarcinoma (AC) is the number one pathological entity of lung cancer with approximately 30-40% of cases. It is known to be heterogeneous and has 5 histopathological growth patterns. We evaluated the long-term survival rates of patients with predominant subtypes. METHODS 290 patients with AC underwent pulmonary resection between 2012 and 2017 at our institution. We excluded all patients with lymph node involvement and distant metastases. Hence, 163 patients were included for further analysis. Predominant growth pattern was defined if more than 10% of cells showed a growth pattern. 1, 3, and 5-year survival rates were evaluated. Survival was assessed by Kaplan-Meier curves and the Cox proportional hazards model was used to identify prognostic factors for overall survival. RESULTS Predominant growth patterns >10% were compared to <10% growth patterns of the same subtype. 1-year, 3-year, and 5-year overall survival rates of patients with predominant solid tumor growth >10% differed significantly from patients with <10% (88.4% vs. 97.6%, p = 0.04; 65.8% vs. 87.4% p = 0.001, 36.4% vs. 65.9% p = 0.01). Survival rates did not differ between >10% papillary and acinar growth compared to <10%. Kaplan-Meier curves showed reduced overall survival for patients with solid tumor growth >10% (log-rank 0.002). Solid tumor growth >10% was an independent prognostic factor for worse long-term survival (Hazard ratio: 3.05, p = 0.01). CONCLUSION Our study demonstrates that the presence of a predominant solid pattern in pulmonary adenocarcinoma is a factor for an unfavorable prognosis. This should be kept in mind in daily clinical practice.
Collapse
Affiliation(s)
- Matthias B Heldwein
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany
| | - Georg Schlachtenberger
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany.
| | - Fabian Doerr
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany
| | - Hruy Menghesha
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany
| | - Gerardus Bennink
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany
| | - Karl-Moritz Schroeder
- School of Medicine, University of Cologne, Cologne, Germany Albertus-Magnus-Platz, 50923, Cologne, Germany
| | - Stephan C Schaefer
- Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany; Institute of Pathology of the Medical Campus Bodensee Roentgen Strasse 2, 88048, Friedrichshafen, Germany
| | - Thorsten Wahlers
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany
| | - Khosro Hekmat
- Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Faculty of Medicine and University Hospital Kerpener Strasse 62, 50937, Cologne, Germany
| |
Collapse
|